Vertex signs $220M deal with Genomics to re-up long-running discovery pact

GettyImages-1096889966.jpg?VersionId=PbYqDzxfR5up5Eh75OZri55Q3FOeYNpJ

Vertex Pharmaceuticals has re-upped its ties with sequencing specialist Genomics in a deal worth up to $220 million, signing on for an extra four years on top of the eight the companies have already worked together.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks